Clinical Trials Arena October 23, 2024
GlobalData Healthcare

Cisgender gay and bisexual men, transgender women, and transgender men remain at higher risk for HIV acquisition.

As groundbreaking studies continue to reshape the human immunodeficiency virus (HIV) landscape, emerging therapies and prevention strategies highlight both progress and the ongoing challenges in the field. Recent findings presented at IDWeek 2024 offered crucial insights into prevention, treatment, and policy for those affected by HIV.

The HIV prevention landscape for cisgender women remains limited despite the availability of options such as emtricitabine/tenofovir disoproxil fumarate, cabotegravir, and the dapivirine ring. While effective, adherence to these methods remains low, and alternatives are needed to fit women’s varied preferences, including solutions for pregnant women. Notably, emtricitabine/tenofovir alafenamide (F/TAF) has yet to receive approval for cisgender...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Clinical Trials, Trends
Transforming Clinical Trials with Alexander Saint-Amand
The New Product Development Landscape: Navigating the Challenges
Lindus Health completes $55m funding round
Bridging Clinical Research Gaps: How Site Augmentation Enhances Trial Success
Key Lead Generation Providers and Technology Solutions for the Clinical Trials Industry

Share This Article